TY - JOUR
T1 - Pharmacokinetics of Phosphatidylethanol 16:0/20:4 in Human Blood After Alcohol Intake
AU - Lopez-Cruzan, Marisa
AU - Roache, John D.
AU - Hill-Kapturczak, Nathalie
AU - Karns-Wright, Tara E.
AU - Dougherty, Donald M.
AU - Sanchez, Jesus J.
AU - Koek, Wouter
AU - Javors, Martin A.
N1 - Funding Information:
This publication was supported by a grant from the NIH National Center for Advancing Translational Sciences grant supplement to ML-C (UL1TR001120-S1). Also, this publication was supported by the National Institute on Alcohol Abuse and Alcoholism of the National Institutes of Health [R01AA022361 and R01AA14988] and, in part, by the National Institute on Drug Abuse [T32DA031115] for postdoctoral training for TEK-W. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. DMD also gratefully acknowledges support from a research endowment, the William and Marguerite Wurz-bach Distinguished Professorship. MAJ gratefully acknowledges support from the Nancy U. Karren Professorship Endowment.
PY - 2018/11
Y1 - 2018/11
N2 - Background: The purpose of this study was to characterize the pharmacokinetics of the phosphatidylethanol (PEth) 16:0/20:4 homolog in uncoagulated human blood samples taken from 18 participants in a clinical laboratory setting after consumption of 2 standard doses of ethanol (EtOH). Methods: Male and female participants received either 0.4 or 0.8 g/kg oral doses of EtOH during a 15-minute period. Blood samples were collected before and throughout 6 hours immediately after alcohol administration and then again at days 2, 4, 7, 11, and 14 of the follow-up period. PEth 16:0/20:4 levels were quantified by high-performance liquid chromatography with tandem mass spectrometry detection. Results: (i) The increase in PEth 16:0/20:4 from baseline to maximum concentration was less than that of PEth 16:0/18:1 or PEth 16:0/18:2 homologs during the 6-hour period after EtOH administration; (ii) the mean half-life of PEth 16:0/20:4 was 2.1 ± 3 (SD) days, which was shorter than the mean half-life of either PEth 16:0/18:1 or PEth 16:0/18:2, 7.6 ± 3 (SD) or 6.8 ± 4 (SD) days, respectively. Conclusions: The pharmacokinetics of PEth 16:0/20:4 in whole blood samples is detectable after alcohol consumption and differs in amount synthesized and rate of elimination versus PEth 16:0/18:1 and 16:0/18:2. Measuring the concentrations of these 3 homologs has the potential to provide more information about the amount and time frame of alcohol consumption than any one alone.
AB - Background: The purpose of this study was to characterize the pharmacokinetics of the phosphatidylethanol (PEth) 16:0/20:4 homolog in uncoagulated human blood samples taken from 18 participants in a clinical laboratory setting after consumption of 2 standard doses of ethanol (EtOH). Methods: Male and female participants received either 0.4 or 0.8 g/kg oral doses of EtOH during a 15-minute period. Blood samples were collected before and throughout 6 hours immediately after alcohol administration and then again at days 2, 4, 7, 11, and 14 of the follow-up period. PEth 16:0/20:4 levels were quantified by high-performance liquid chromatography with tandem mass spectrometry detection. Results: (i) The increase in PEth 16:0/20:4 from baseline to maximum concentration was less than that of PEth 16:0/18:1 or PEth 16:0/18:2 homologs during the 6-hour period after EtOH administration; (ii) the mean half-life of PEth 16:0/20:4 was 2.1 ± 3 (SD) days, which was shorter than the mean half-life of either PEth 16:0/18:1 or PEth 16:0/18:2, 7.6 ± 3 (SD) or 6.8 ± 4 (SD) days, respectively. Conclusions: The pharmacokinetics of PEth 16:0/20:4 in whole blood samples is detectable after alcohol consumption and differs in amount synthesized and rate of elimination versus PEth 16:0/18:1 and 16:0/18:2. Measuring the concentrations of these 3 homologs has the potential to provide more information about the amount and time frame of alcohol consumption than any one alone.
KW - Alcohol
KW - Blood
KW - High-Performance Liquid Chromatography/Mass Spectrometry/Mass Spectrometry
KW - Pharmacokinetics
KW - Phosphatidylethanol
UR - http://www.scopus.com/inward/record.url?scp=85052396421&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85052396421&partnerID=8YFLogxK
U2 - 10.1111/acer.13865
DO - 10.1111/acer.13865
M3 - Article
C2 - 30091144
AN - SCOPUS:85052396421
VL - 42
SP - 2094
EP - 2099
JO - Alcoholism: Clinical and Experimental Research
JF - Alcoholism: Clinical and Experimental Research
SN - 0145-6008
IS - 11
ER -